Some of the detected fusions have been previously reported in infiltrating gliomas, including MET-PTPRZ1, which was detected in 3 cases (2 IDH-mutant and 1 IDH-wildtype case), FGFR1-TACC1 (1 IDH-wildtype case), and FGFR3-TACC3 in 8 cases (6 IDH-wildtype infiltrating astrocytomas, 1 neuroendocrine tumor NOS, and one malignant neoplasm, NOS) (Fig. 4a). This evidence concerns the gene MET and central nervous system cancer.